Importance A significant proportion of patients with early-stage triple-negative breast cancer
(TNBC) are treated with neoadjuvant chemotherapy. Sequencing of circulating tumor DNA
(ctDNA) after surgery, along with enumeration of circulating tumor cells (CTCs), may be used
to detect minimal residual disease and assess which patients may experience disease
recurrence. Objective To determine whether the presence of ctDNA and CTCs after
neoadjuvant chemotherapy in patients with early-stage TNBC is independently associated …